A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol.

Takashi MoritoyoNaoko NishimuraKeiko HasegawaShinya IshiiKenji KiriharaMunenori TakataAkiko Kishi SvenssonYumi Umeda-KameyamaShuichi KawarasakiRyoko IharaChie SakanakaYurie WakabayashiKuniyasu NiizumaTeiji TominagaTsutomu YamazakiKeiji Hasumi

Published in: British journal of clinical pharmacology (2022)

TMS-007 is generally well tolerated and exhibits favourable pharmacokinetic profiles that warrant further clinical development.

Keyphrases

transcranial magnetic stimulation
anti inflammatory
endothelial cells
induced pluripotent stem cells
high frequency